Global Hepatitis Drugs Market 2015-2019

2015-12-09
Price :
Published : Dec-2015
No. of Pages : 118

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

The analysts forecast global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.

The report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Vertex Pharmaceuticals

Other prominent vendors

  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Dynavax Technologies
  • Mitsubishi Tanabe Pharma

Key market driver

  • Emergence of IFN-free therapies
  • For a full, detailed list, view our report

Key market challenge

  • Side-effects of current therapy
  • For a full, detailed list, view our report

Key market trend

  • Collaborations and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026 Summary GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development. In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes ......
$3995

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017). Our epidemiologists forecast an increase in the diagnosed inciden......
$3995

Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Chlamydia Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Chlamydia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Chlamydia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team o......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the......
$3500

Bone Metastasis Global Clinical Trials Review, H1, 2017

Bone Metastasis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bone Metastasis Global Clinical Trials Review, H1, 2017" provides an overview of Bone Metastasis clinical trials scenario. This report provides top line data relating to the clinical trials on Bone Metastasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Brenner Tumor Global Clinical Trials Review, H1, 2017

Brenner Tumor Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Brenner Tumor Global Clinical Trials Review, H1, 2017" provides an overview of Brenner Tumor clinical trials scenario. This report provides top line data relating to the clinical trials on Brenner Tumor. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Burkitt Lymphoma Global Clinical Trials Review, H1, 2017

Burkitt Lymphoma Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Burkitt Lymphoma Global Clinical Trials Review, H1, 2017" provides an overview of Burkitt Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Burkitt Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Bone Sarcoma Global Clinical Trials Review, H1, 2017

Bone Sarcoma Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bone Sarcoma Global Clinical Trials Review, H1, 2017" provides an overview of Bone Sarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Bone Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Bronchiectasis Global Clinical Trials Review, H1, 2017

Bronchiectasis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bronchiectasis Global Clinical Trials Review, H1, 2017" provides an overview of Bronchiectasis clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchiectasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Burns Global Clinical Trials Review, H1, 2017

Burns Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Burns Global Clinical Trials Review, H1, 2017" provides an overview of Burns clinical trials scenario. This report provides top line data relating to the clinical trials on Burns. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ di......
$2500